ArticleClinical, cosmetic and investigational dermatology2024
Dermatologists' Perceptions and Factors Influencing the Selection of Topical Anti-Inflammatory Agents for Atopic Dermatitis in China: A Cross-Sectional Survey Study.
Article in Clinical, cosmetic and investigational dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE-4) inhibitors are three common topical anti-inflammatory agents for treating atopic dermatitis (AD). The purpose of our study was to understand Chinese dermatologists' perceptions and the factors influencing their choices of the three agents. Methods: An online questionnaire survey was conducted between 25 July 2022 and 25 August 2022 among Chinese dermatologists. The survey with six multiple-choice questions focused on what were their most commonly prescribed agents for treating AD, and what factors influenced their choices of the three agents. The results were assessed by chi-square test and logistic regression analysis. Results: A total of 1, 156 valid questionnaire replies were received. For treating AD, 79.84% of Chinese dermatologists chose TCS, 81.40% chose TCI, and 18.25% chose PDE-4 inhibitors. When TCS was not chosen, the three principal reasons included local adverse effects (85.56%), suspicious infection on lesioned area (71.54%), and patient steroid phobia (61.59%). Coincidentally, when the TCI and PDE-4 inhibitors were chosen, the main reason was patient steroid phobia (76.21% and 74.74% respectively) against TCS. When PDE-4 inhibitors were not chosen, the major reasons were their intolerable adverse effects (80.36%) and their slower onset and weak efficacy (57.61%). Logistic regression analysis revealed that more senior dermatologists were less likely to choose TCS for the reason of local adverse effects and patient steroid phobia (each Conclusion: Local adverse effects and patient steroid phobia were the reasons that limited Chinese dermatologists from choosing TCS for treating AD. Instead, more of them choose to use TCI. PDE-4 inhibitors were sometimes considered as an alternative to TCS or TCI, but its local adverse effects and limited efficacy affected the choice of this agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.